Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer

TOP - January 2022 Vol 15, No 1 – Online Only - Colorectal Cancer

Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial. All patients had metastatic CRC with KRASG12C mutations and had received previous treatment.

The response rate to adagrasib monotherapy was 22% and response to the combination of adagrasib plus cetuximab was 43% (confirmed later as 39%). The disease control rate was 100%.

KRAS, a target formerly considered undruggable, now has 1 KRASG12C inhibitor approved for the treatment of lung cancer by the FDA—sotorasib (Lumakras). Several other KRASG12C inhibitors are in development.

“Adagrasib is tolerable and has a manageable safety profile, both as monotherapy and in combination with cetuximab,” said lead author Jared Weiss, MD, Section Chief, Thoracic and Head/Neck Oncology, and Research Leader, Thoracic Oncology, University of North Carolina-Chapel Hill, speaking at a Presidential Symposium of the European Society for Medical Oncology Congress 2021.

KRASG12C mutations are present in 3% to 4% of all cases of CRC. These mutations act as oncogenic drivers and are a negative predictor of cetuximab efficacy. Adagrasib irreversibly and selectively binds to KRASG12C. The drug was designed to have a long half-life, dose-dependent pharmacokinetics, and brain penetration.

Dr Weiss explained that the combination of adagrasib plus the EGFR inhibitor cetuximab “may enhance the inhibition of KRAS-dependent signaling or overcome adaptive feedback to improve outcomes.”

Study Results

The multicohort KRYSTAL-1 study evaluated adagrasib in 78 patients with solid tumors harboring KRASG12C mutations who had no other treatment options. These included 46 patients with previously treated CRC who received adagrasib 600 mg twice daily as monotherapy and 32 patients who received adagrasib in combination with cetuximab. More than 50% of the patients had received ≥3 previous lines of therapy; 69% had TP53 mutations, and 15% to 20% of the patients had other mutations. The median follow-up was 8.9 months for the monotherapy cohort and 7 months for the combination cohort.

In the adagrasib monotherapy cohort, the objective response rate (ORR) was 22% and the disease control rate was 87% (including complete response, partial response, or stable disease). The response rates were much higher in the combination cohort; 32 patients who received the combination of adagrasib plus cetuximab had an ORR of 43% and a disease control rate of 100%.

In the monotherapy cohort, the median duration of response was 4.2 months, and at the time of analysis, 40% were still receiving treatment. The median progression-free survival was 5.6 months, and at 6 months, 42% had no disease progression.

In the combination cohort, after data cutoff, 1 or 2 patients with unconfirmed response achieved a confirmed response, for a total confirmed response rate of 39%. All the other patients in this cohort had stable disease.

“In the combination cohort, 71% of patients remained on treatment. The data are too immature for a meaningful analysis of duration of response or progression-free survival in this cohort,” Dr Weiss said.

No association was found between co-mutational status and response.

Adagrasib as monotherapy and in combination with cetuximab was well-tolerated. Grade 3/4 treatment-related adverse events were reported in 30% of the monotherapy cohort and 16% of the combination cohort. Combination treatment led to dermatitis and rash of any grade in 44% and 22%, respectively.

Adagrasib plus cetuximab is being evaluated in the second-line setting, in a phase 3 trial of patients with CRC and KRASG12C mutation.

Expert Commentary

Invited discussant Federica Di Nicolantonio, MD, PhD, Associate Professor, Oncology Department, University of Turin, Italy, noted that adagrasib and sotorasib (another KRASG12C inhibitor) achieve higher response rates in non–small-cell lung cancer than in metastatic CRC. “This is reminiscent of what has been observed with BRAF inhibitors—about 50% of patients with metastatic melanoma respond compared with about 5% of metastatic CRC.”

KRASG12C inhibitors as monotherapy yield a relatively low ORR, but when you combine them with an KRAS inhibitor, the response rate is nearly double,” Dr Di Nicolantonio said. “There is a striking synergy in mouse models.”

“We eagerly await the results of the phase 3 KRYSTAL-10 trial of second-line adagrasib plus cetuximab versus conventional chemotherapy [in metastatic CRC]. We are also eager to see other combinations of KRASG12C inhibitors for which we have solid preclinical data,” she said.

Related Items
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on February 28, 2022 in COVID-19 & Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Prostate Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Neuroblastoma
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Pathogenic Germline Variants Identified in Children with Neuroblastoma
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Genetic Counseling
Last modified: February 22, 2022